These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35299182)

  • 1. [Ⅲ. Novel Treatment Targeting CSF1-R for Tenosynovial Giant Cell Tumor].
    Takeuchi A; Tsuchiya H
    Gan To Kagaku Ryoho; 2022 Mar; 49(3):277-281. PubMed ID: 35299182
    [No Abstract]   [Full Text] [Related]  

  • 2. Vimseltinib for tenosynovial giant cell tumour.
    Urakawa H; Imagama S
    Lancet; 2024 Jun; 403(10445):2665-2667. PubMed ID: 38843859
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
    van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
    J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Tenosynovial Giant Cell Tumor of the Flexor Hallucis Longus Tendon Sheath: A Case Report.
    Williams RD; Honeycutt MW; Manci EA; Nimityongskul P
    JBJS Case Connect; 2020; 10(2):e0519. PubMed ID: 32649117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
    Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
    Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Cai W; Yang L; Li J; Li Q
    Asian J Surg; 2023 Dec; 46(12):6033-6034. PubMed ID: 37777406
    [No Abstract]   [Full Text] [Related]  

  • 9. Tenosynovial giant cell tumour of the hand in children under 10 years of age.
    Tsujino S; Matsumoto S; Ae K
    J Hand Surg Eur Vol; 2018 Mar; 43(3):335-337. PubMed ID: 29105587
    [No Abstract]   [Full Text] [Related]  

  • 10. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
    Caldwell TM; Ahn YM; Bulfer SL; Leary CB; Hood MM; Lu WP; Vogeti L; Vogeti S; Kaufman MD; Wise SC; Le Bourdonnec B; Smith BD; Flynn DL
    Bioorg Med Chem Lett; 2022 Oct; 74():128928. PubMed ID: 35961460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Treatment for Tenosynovial Giant Cell Tumor of the Hand.
    Kitagawa Y; Takai S
    J Nippon Med Sch; 2020 Sep; 87(4):184-190. PubMed ID: 32350187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
    Chan AS; Katiyar V; Dy P; Singh V
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extra-articular tenosynovial giant cell tumor of diffuse type in the temporal area with brain parenchymal invasion: a case report.
    Son SM; Park YS; Choi CH; Lee HC; Lee OJ; Woo CG
    Br J Neurosurg; 2018 Dec; 32(6):688-690. PubMed ID: 29334779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel
    Mejbel H; Siegal GP; Wei S
    Int J Surg Pathol; 2022 May; 30(3):335-338. PubMed ID: 34657489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
    Mastboom MJL; Palmerini E; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Staals EL; Schaap GR; Jutte PC; Aston W; Gelderblom H; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; ; van de Sande MAJ
    Lancet Oncol; 2019 Jun; 20(6):877-886. PubMed ID: 31029509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
    Thangaiah JJ; Koepplin JW; Folpe AL
    Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenosynovial giant cell tumor in the foot and ankle.
    Çevik HB; Kayahan S; Eceviz E; Gümüştaş SA
    Foot Ankle Surg; 2020 Aug; 26(6):712-716. PubMed ID: 31526689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.